Recently, Sinopharm announced that its innovative biological drug, recombinant teriparatide for injection (Sinfutai Plus® ) , has been approved by the National Medical Products Administration for the treatment of osteoporosis in postmenopausal women at high risk of fractures.

Osteoporosis is a systemic bone disease with a high incidence and great harm, especially among postmenopausal women. It is characterized by low bone mass and destruction of bone tissue microstructure, leading to increased bone fragility and easy fractures. According to estimates, there are currently about 90 million people with osteoporosis in China, of which about 70 million are women.

The main treatment goal for osteoporosis is to reduce the risk of fractures. Teriparatide helps promote bone formation, increase bone density, and improve bone quality, providing a new option for osteoporosis patients with extremely high risk of fractures and has been recommended by domestic and international guidelines [2] . Xinfutai Plus® ( recombinant teriparatide for injection) is the first teriparatide weekly preparation to be marketed in China. It is a powder injection administered subcutaneously once a week. Currently, there are no products with the same specifications and dosage on the market in China. Previously, the company had Xinfutai Pro® (teriparatide injection) for once-daily use , which has accumulated good brand awareness in the bone formation promoter market.

The newly approved weekly formulation will further improve patient medication adherence, provide a new option for the full course of bone formation promoters, improve the company's bone formation promoter product portfolio, enrich the product pipeline in the field of osteoporosis treatment, enhance the company's overall competitiveness in the field of chronic disease treatment, and serve a wider range of patients.

Regarding osteoporotic fractures
“
Osteoporotic fractures (or fragility fractures) are fractures that occur from minor trauma (equivalent to a fall from standing height or less) and are a serious consequence of osteoporosis. Common sites for osteoporotic fractures include the vertebrae, distal forearm, hip, proximal humerus, and pelvis, with vertebral fractures being the most common. Osteoporotic fractures are extremely dangerous and are one of the leading causes of disability and death in elderly patients. Research data shows that within one year of a hip fracture, 20% of patients may die from various complications; approximately 50% of patients become disabled, experiencing a significant decline in their quality of life.

https://mp.weixin.qq.com/s/keURVn6A0EeIdY5gZsuONw